Obesity War: Novo Nordisk (Ozempic) sues Eli Lilly for misleading advertising
The battle to dominate the global market for obesity drugs has moved from laboratories to courts. Danish pharmaceutical company Novo Nordisk has sued Eli Lilly in the U.S. for alleged misleading advertising, claiming that its promotional campaigns present “false and materially misleading” comparisons between the treatments of both companies, to make it appear that its product yielded better results.